The first months of 2025 brought a familiar mix of challenges and transitions to Grand County, with public lands, water, housing and tourism again at the center of local conversation. New elected leadership and early policy shifts quickly reshaped county …

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment- …

… than $150 billion in revenue by the early 2030s, … obesity, giving the Danish drugmaker a competitive edge ‌in … obesity treatment market. Several drugmakers are racing to develop an … first half of next year. MERCK The company, in partnership with Hansoh Pharma …

… the registrational study in the first half of 2026, pending finalization … See LXEO stock forecast) Phathom Pharmaceuticals (PHAT) Next up is … market gives Phathom a meaningful revenue base. To date, … line of sight to operating profitability (non-GAAP) in 2026 …

Many healthcare administrators know the numbers by heart: recruiting a single registered nurse costs around $60,000 and up to $71,000 or more, according to the 2025 NSI National Health Care Retention & RN Staffing Report, when accounting for agency …

… Pharmaceuticals Plc recorded a strong nine-month 2025 performance, posting revenue …  N166.2 million. All revenue was generated within Nigeria. … supported earnings, lifting operating profit to N1.6 billion, … so far and lifting first-half gains to 185.15%, …

… US$2.2 billion: French drugmaker Sanofi has agreed to buy … plus additional payments tied to profit. Global Panduro says the deal … expected to close in the first half of 2026.

… , as demand recovery broadens and revenue growth improves. Industrials and capital … -led adoption. Healthcare and select pharmaceutical stocks offer defensive growth and … over weak earnings dominated the first half of FY26, Q2 results showed …

Dive Brief: Medtronic’s planned diabetes device spinoff MiniMed has filed for an initial public offering, the company said Friday. The filing shows MiniMed made a $198 million loss on sales of $2.72 billion in its 2025 fiscal year. MiniMed plans to grow …

… nutrition throughout the month. The first half (flax and pumpkin for zinc … fill a dietary — not a pharmaceutical — void. She clarifies that this … a kitchen experiment into a profitable venture rooted in information. Keerthi …